Feasibility of Individualized Therapy for Recurrent GBM
Status:
Recruiting
Trial end date:
2027-01-31
Target enrollment:
Participant gender:
Summary
The current study will test the ability and likelihood of successfully implementing
individualized combination treatment recommendations for adult patients with
surgically-resectable recurrent glioblastoma in a timely fashion. Collected tumor tissue and
blood will be examined using a new diagnostic testing called University of California, San
Francisco (UCSF) 500 Cancer Gene Panel which is done at the UCSF Clinical Cancer Genomics
Laboratory. The UCSF 500 Cancer Gene Panel will help identify genetic changes in the DNA of a
patient's cancer, which helps oncologists improve treatment by identifying targeted
therapies.